Summary

US Inhalation Anesthesia Market is valued at approximately USD 587.77 million in 2023 and is anticipated to grow with a healthy growth rate of more than 9.77% over the forecast period 2024-2032. The Inhalation Anesthesia Market in the US is characterized by continuous advancements in anesthesia delivery systems and increasing demand for surgical procedures. Inhalation anesthesia involves administering volatile anesthetic agents through inhalation to induce and maintain general anesthesia during surgeries, ensuring patient comfort and safety. A significant trend in this market is the rapid adoption of technological innovations in anesthesia delivery systems, such as smart monitoring devices and closed-loop anesthesia systems. These innovations enhance the safety, precision, and efficiency of anesthesia administration, leading to improved patient outcomes and surgical experiences. Additionally, the growing number of surgical procedures, including minimally invasive surgeries and outpatient interventions, contributes to the rising utilization of inhalation anesthesia. These trends collectively shape the landscape of the Inhalation Anesthesia Market in the US, reflecting a growing commitment to advancing surgical care while prioritizing patient well-being.

The US Inhalation Anesthesia Market is driven by technological advancements in anesthesia delivery systems and the increasing demand for surgical procedures. Continuous innovations in anesthesia delivery systems, such as smart monitoring devices and closed-loop anesthesia systems, enhance the safety, precision, and efficiency of anesthesia administration, ultimately improving patient outcomes and surgical experiences. Concurrently, the rising number of surgical procedures in the US, including minimally invasive surgeries and outpatient interventions, fuels the demand for inhalation anesthesia. Also, ongoing research and development efforts to improve the safety, efficacy, and accessibility of inhalation anesthesia while addressing regulatory and economic constraints. However, potential adverse effects associated with prolonged anesthesia exposure, stringent regulatory requirements for drug approval, and pricing pressures within healthcare systems, on the other hand, stifle market growth between 2022 and 2032.


Major market player included in this report are:
Drägerwerk AG & Co. KGaA
Baxter International Inc.
AbbVie Inc.
Fresenius SE & Co. KGaA
Piramal Enterprises Limited
Halocarbon Products Corporation
Cardinal Health Inc.
GE Healthcare
Merck KGaA
B. Braun Melsungen AG


The detailed segments and sub-segment of the market are explained below:

By Type
Desflurane
Sevoflurane, Isoflurane
Other Types

By End-user
Hospital
Ambulatory Surgical Centers
Other End Users



Years considered for the study are as follows:
Historical year – 2022
Base year – 2023
Forecast period – 2024 to 2032

Key Takeaways:
Market Estimates & Forecast for 10 years from 2022 to 2032.
Annualized revenues and Country level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market

ページTOPに戻る

Table of Contents

Chapter 1. US Inhalation Anesthesia Market Definition and Research Assumptions
1.1. Research Objective
1.2. Market Definition
1.3. Research Assumptions
1.3.1. Inclusion & Exclusion
1.3.2. Limitations
1.3.3. Supply Side Analysis
1.3.3.1. Availability
1.3.3.2. Infrastructure
1.3.3.3. Regulatory Environment
1.3.3.4. Market Competition
1.3.3.5. Economic Viability (Consumer’s Perspective)
1.3.4. Demand Side Analysis
1.3.4.1. Regulatory frameworks
1.3.4.2. Technological Advancements
1.3.4.3. Environmental Considerations
1.3.4.4. Consumer Awareness & Acceptance
1.4. Estimation Methodology
1.5. Years Considered for the Study
1.6. Currency Conversion Rates

Chapter 2. Executive Summary
2.1. US Inhalation Anesthesia Market Size & Forecast (2022- 2032)
2.2. Segmental Summary
2.2.1. By Type
2.2.2. By End-user
2.3. Key Trends
2.4. Recession Impact
2.5. Analyst Recommendation & Conclusion
Chapter 3. US Inhalation Anesthesia Market Dynamics
3.1. Market Drivers
3.2. Market Challenges
3.3. Market Opportunities
Chapter 4. US Inhalation Anesthesia Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model
4.1.7. Porter’s 5 Force Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top investment opportunity
4.4. Top winning strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspective
4.7. Analyst Recommendation & Conclusion
Chapter 5. US Inhalation Anesthesia Market Size & Forecasts by Type 2022-2032
5.1. Desflurane
5.2. Sevoflurane
5.3. Isoflurane
5.4. Other Types
Chapter 6. US Inhalation Anesthesia Market Size & Forecasts by End-user 2022-2032
6.1. Hospital
6.2. Ambulatory Surgical Centers
6.3. Other End Users
Chapter 7. Competitive Intelligence
7.1. Key Company SWOT Analysis
7.1.1. Company 1
7.1.2. Company 2
7.1.3. Company 3
7.2. Top Market Strategies
7.3. Company Profiles
7.3.1. Drägerwerk AG & Co. KGaA
7.3.1.1. Key Information
7.3.1.2. Overview
7.3.1.3. Financial (Subject to Data Availability)
7.3.1.4. Product Summary
7.3.1.5. Market Strategies
7.3.2. Baxter International Inc.
7.3.3. AbbVie Inc.
7.3.4. Fresenius SE & Co. KGaA
7.3.5. Piramal Enterprises Limited
7.3.6. Halocarbon Products Corporation
7.3.7. Cardinal Health Inc.
7.3.8. GE Healthcare
7.3.9. Merck KGaA
7.3.10. B. Braun Melsungen AG
Chapter 8. Research Process
8.1. Research Process
8.1.1. Data Mining
8.1.2. Analysis
8.1.3. Market Estimation
8.1.4. Validation
8.1.5. Publishing
8.2. Research Attributes